Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna Oral Lesion Identification Coverage Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0760

    Oral Screening and Lesion Identification Systems

    Customize your policy alerts

    Sign up for Aetna Policy 0760 alerts

    Get alerted when Policy 0760 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for oral screening and lesion identification systems and related adjunctive tests for early detection of oral cancer and premalignant lesions; applies to clinical use by providers performing oral screening and diagnostic adjuncts.

    Policy Summary
    PayerAetna
    PolicyOral Screening and Lesion Identification Systems
    Policy CodePolicy 0760
    Change TypeNo material change
    Effective DateJul 1, 2008
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not use adjunctive devices or salivary/HPV/EBV tests as substitutes for comprehensive oral examination and confirmatory scalpel biopsy; document exam findings and rationale for biopsy when indicated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2008policy effective
    2023-10-11last review
    2024-08-22next review
    ~28,900US cases/yr
    ≈0.91cytology sens

    Coverage Criteria and Evidence Summary

    Experimental and Investigational

    The following procedures are considered experimental and investigational because the effectiveness has not been established:

    Experimental/Investigational List: Epstein-Barr virus (EBV) testing for screening for oral squamous cell carcinoma; oral human papillomavirus (HPV) testing (e.g., OraRisk HPV Salivary DNA Test) for all indications; salivary biomarkers (DUSP100, IL-1B, IL-8, MMP-9, microRNA, mRNA, s100P, TNF-alpha) for screening and detection of oral squamous cell carcinomas; salivary hypermethylated DNA biomarkers; salivary metabolite biomarkers for screening of OSCC and oral epithelial dysplasia from persistent suspicious lesions; tumor-derived exosomal (TEX) biomarkers from liquid biopsy; chemiluminescence; confocal laser endomicroscopy; diffuse reflectance spectroscopy; fluorescence spectroscopy; MOP genetic testing; narrow band imaging; optical filter for autofluorescence (GOCCLES); optical fluorescence imaging (e.g., 5-ALA induced PpIX fluorescence, autofluorescence); oral lesion identification systems (e.g., Dentlight Oral Exam Light Kit, Microlux DL, Orascoptic DK, Sapphire Plus, TRIMIRA Identafi 3000, ViziLite-Blue, VELscope); Straticyte; wide-field and high-resolution in-vivo imaging; and salivary metabolite biomarkers.

    Listed verbatim as experimental/investigational in policy

    Coverage considerations and clinical role

    Coverage and clinical use considerations based on evidence presented

    Policy Summary
    PayerAetna
    PolicyOral Screening and Lesion Identification Systems
    Policy CodePolicy 0760
    Change TypeNo material change
    Effective DateJul 1, 2008
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not use adjunctive devices or salivary/HPV/EBV tests as substitutes for comprehensive oral examination and confirmatory scalpel biopsy; document exam findings and rationale for biopsy when indicated.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryCoding and BillingProvider Responsibilities, Documentation, and AuthorizationBackground and ContextDefinitions and Device DescriptionsPolicy Revision History
    Adjunctive devices are supplemental: Adjunctive imaging devices (chemiluminescence, autofluorescence, tissue reflectance, spectroscopy and related optical aids) are intended as aids to a comprehensive oral examination (COE) and are not replacements for clinical examination and scalpel biopsy/histopathology.

    Supported by multiple systematic reviews and guidelines

    Utility limited or uncertain: Systematic reviews and guideline evaluations report inconsistent results, high risk of bias in many studies, and insufficient evidence that adjunctive devices improve diagnostic accuracy or reduce oral cancer mortality in screening settings; methods cannot substitute for biopsy.

    Cochrane review, USPSTF, ADA and recent systematic reviews cited

    Potential adjunctive role in selected settings: In selected high-risk populations or specialist settings some devices (for example, VELscope) may increase sensitivity or assist margin delineation, but specificity is variable and findings require interpretation by experienced clinicians with confirmatory biopsy when indicated.

    Examples: margin assessment, high-risk cohorts; evidence limited and heterogeneous

    Adjunctive imaging — evidence summary

    Findings from systematic reviews and studies summarized in this section:

    Adjunctive non-invasive imaging performance and limitations: Autofluorescence devices (eg, VELscope) and fluorescent probes (eg, 5-ALA) demonstrate highly variable sensitivity and specificity across studies (VELscope sensitivity reported ~33%–100% and specificity ~12%–88.6%; 5-ALA sensitivity commonly high 90%–100% with variable specificity). Some techniques such as fluorescence spectroscopy (FS), diffuse reflectance spectroscopy (DRS), and 5-ALA induced PpIX show higher reported accuracy for differentiating dysplastic OPMDs from non-dysplastic lesions in pooled analyses, but studies are heterogeneous, often small, lack standardized protocols, and cannot replace histopathology. Standardization of protocols, larger prospective validation studies, and assessment of clinical and economic impact are needed before these methods can be considered diagnostic substitutes for biopsy.

    Summary of Lima et al, Dos Santos et al, Mendonca et al, GOCCLES and others; highlights performance ranges and need for validation

    The policy lists multiple adjunctive technologies and biomarker assays that are considered experimental and investigational because their clinical effectiveness for early detection or diagnosis of oral cancer has not been established. Examples explicitly named include EBV antibody testing, oral HPV testing (e.g., OraRisk), numerous salivary biomarkers and hypermethylated DNA markers, tumor-derived exosomal biomarkers, and a range of device- and imaging-based aids (eg, chemiluminescence, confocal laser endomicroscopy, diffuse reflectance and fluorescence spectroscopy, narrow band imaging, optical fluorescence imaging including 5‑ALA induced PpIX and autofluorescence, GOCCLES, and commercial oral lesion identification systems such as ViziLite-Blue and VELscope). These listed technologies are therefore not supported for coverage under this policy.

    Systematic reviews and guideline statements indicate that no evaluated imaging-based adjunct can substitute for a tissue diagnosis by biopsy and histopathology. A 2022 systematic review found inconsistent results across studies, high risk of bias, and concluded that none of the evaluated imaging methods could replace oral biopsy. Earlier reviews and guidance similarly note insufficient evidence to support routine population screening with adjunctive devices and recommend that these tools be used only as supplements to a comprehensive clinical oral examination (COE).

    Screening for oral HPV infection is not recommended by major medical and dental organizations, and no FDA‑approved screening test for oral HPV infection currently exists. Although detection of oral HPV is an area of active research, available guidance does not support routine screening of asymptomatic populations for oral HPV.

    Adjunctive tests such as vital staining, brush cytology and light‑based detection have not demonstrated sufficient quality of evidence to replace scalpel biopsy. Meta-analyses show variable accuracy across methods and overall study quality is poor; therefore, these adjunctive modalities cannot supplant histologic assessment as the definitive diagnostic standard.

    Optical fluorescence, cytology and biomarker assays are discussed in the literature as potential adjuncts, but current evidence does not support their use as replacements for surgical biopsy and histopathological evaluation. Even when adjuncts provide immediate or less invasive results, confirmatory biopsy remains necessary to establish diagnosis and guide management.

    Many salivary techniques and candidate biomarkers lack clinical validation, standardization, and robust prospective evidence. Studies frequently used research‑use‑only ELISA reagents, had heterogeneous methods of saliva collection and assay, small sample sizes, and variable reporting of diagnostic metrics. These limitations mean numerous salivary assays and other biomarkers remain unvalidated for routine clinical use.

    Across imaging and probe-based adjuncts, authors consistently conclude that these techniques are unable to replace histopathological examination for definitive diagnosis. While some modalities (eg, certain fluorescent probes or spectroscopic methods) may show promising sensitivity or specificity in select studies, methodological heterogeneity, small cohorts, and lack of prospective outcome data preclude substituting imaging-based findings for biopsy and histology.

    Adjunctive imaging devices should be considered aids to, not substitutes for, a comprehensive oral examination and targeted tissue biopsy. Guideline and systematic review conclusions emphasize that clinical decision-making should rely on COE and confirmatory histopathology; using adjunctive imaging as a standalone substitute for biopsy is unsupported by the evidence.

    Computer‑aided cytology, liquid‑based cytology, and other adjunctive technologies have not demonstrated sufficient, consistent evidence to be recommended as replacements for scalpel biopsy. Systematic reviews identify oral cytology as having potential diagnostic value but do not endorse any adjunctive technique as a definitive alternative to histopathology.

    The evidence does not support use of autofluorescence devices or fluorescent probes as standalone replacements for biopsy and histopathology to establish malignancy. Systematic reviews report variable performance metrics, lack of standardized fluorescence measurement thresholds, and frequent methodological limitations that preclude recommending these modalities as definitive diagnostic tests.

    Coding and Billing

    Not covered/identified CPT codes associated with adjunctive testingCPTNot Covered
    40899Unlisted procedure, vestibule of mouth
    41599Unlisted procedure, tongue, floor of mouth
    41899Unlisted procedure, dentoalveolar structures
    82397Chemiluminescent assay
    87623Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44)
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
    HCPCS codes referencedHCPCSNot Covered
    D0431Adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including premalignant and malignant lesions, not to include cytology or biopsy procedures
    G0476Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types for cervical cancer screening, must be performed in addition to pap test
    ICD-10 codes noted in policy (not covered for listed indications)ICD-10
    A69.0Chancroid (example code listed in ICD-10 not covered list context)
    K00.0-K14.9Disease of oral cavity, salivary glands, and jaws
    C00.0-C10.9Malignant neoplasm of lip and oral cavity
    D00.00-D00.08Carcinoma in situ of lip, oral cavity, and pharynx
    D37.01-D37.02, D37.04-D37.09Neoplasm of uncertain behavior of lip, oral cavity, and pharynx
    Z12.81Encounter for screening for malignant neoplasms of oral cavity
    EBV antibody testing codesCPTNot Covered
    86663-86665Antibody; Epstein-Barr (EB) virus

    Provider Responsibilities, Documentation, and Authorization

    Billing Rule

    Coding and coverage identification

    Coding and coverage identification — Codes associated with listed adjunctive tests and unlisted oral procedures are identified in this policy. Providers should bill the applicable CPT/HCPCS/ICD-10 codes noted in the policy; services for technologies or indications described as experimental/investigational or not supported by the policy may be denied.

    • Relevant CPT/HCPCS examples: 40899, 41599, 41899 (unlisted oral procedures); 82397 (chemiluminescent assay); 87623-87625 (HPV NAATs); HCPCS D0431 (adjunctive pre-diagnostic test); G0476.
    • ICD-10 examples noted as not covered for screening indications: Z12.81; C00.0-C10.9; D00.00-D00.08; D37.01-D37.09; K00.0-K14.9.
    Denial Risk

    Denial risk for experimental/investigational technologies

    Denial risk for experimental/investigational technologies — Use of procedures or assays described as experimental, investigational, pre-market, research-use-only, or lacking sufficient clinical validation may result in claim denial. Confirm plan-specific coverage before ordering or billing.

    • Examples include Straticyte™ (pre-market), many salivary biomarker assays using RUO ELISA kits, novel microRNA or hypermethylated DNA panels, and certain optical/fluorescent probes without demonstrated clinical utility.
    • Providers should verify medical necessity and local plan criteria; absence of stated coverage in the Clinical Policy Bulletin does not guarantee payment.
    Note

    Clinical validation required

    Clinical validation required — Many salivary assays, biomarker tests, and novel adjunctive technologies lack standardized collection, analytic validation, and robust prospective clinical validation. Such tests should not be used as replacements for histopathology and may be considered investigational until validated.

    • Salivary cytokine and hypermethylated DNA studies show heterogeneity and use RUO reagents; standardization of saliva collection and assay platforms is needed.
    • Stratified, multi-center prospective data demonstrating diagnostic accuracy and clinical utility are required before routine clinical adoption.
    Prior Authorization

    Plan-level prior authorization

    Plan-level prior authorization — This Clinical Policy Bulletin provides guidance but does not itself establish prior authorization. Providers must follow plan-specific prior authorization requirements and check benefit documents or prior authorization portals before performing adjunctive tests or novel assays.

    • Policy bulletin content does not replace plan administrative rules; contact the member's plan for authorization requirements.
    • Failure to obtain required prior authorization may lead to claim denial or member liability.
    Prior Authorization

    Prior authorization

    Prior authorization — No universal prior authorization is specified in this section; however, some tests or procedures (particularly novel assays, unlisted procedures, or experimental technologies) may require prior authorization under the member’s plan.

    • Verify prior authorization requirements for unlisted procedure codes (e.g., 40899, 41599, 41899) and for biomarker/diagnostic codes before scheduling.
    • Document clinical rationale and supporting records when seeking authorization.
    Denial Risk

    Insufficient evidence that routine screening reduces mortality

    Insufficient evidence that routine screening reduces mortality — Systematic reviews and USPSTF guidance indicate insufficient evidence to recommend routine population screening for oral cancer using adjunctive devices or tests; routine screening outside established guidelines risks unsupported care.

    • Professional bodies do not recommend routine oral HPV screening; no FDA-approved oral HPV screening tests exist.
    • Routine use of adjunctive devices without appropriate clinical indications may not improve outcomes and can risk denial.
    Documentation Required

    Adjunctive tests are not definitive

    Adjunctive tests are not definitive — Adjunctive devices and tests (autofluorescence, chemiluminescence, toluidine blue, brush cytology, optical filters, salivary biomarkers) are aids to clinical assessment and are not replacements for scalpel biopsy and histopathologic diagnosis.

    • None of the evaluated adjunctive methods can substitute for surgical biopsy and histological assessment; oral cytology shows promise but is not definitive.
    • Adjunctive findings should be used to guide clinical judgment and decisions about referral and biopsy.
    Note

    Adjunctive tools are not a substitute; devices are aids

    Adjunctive tools are not a substitute; adjunctive devices are aids — Use adjunctive devices only in conjunction with a comprehensive clinical oral examination (COE). They may assist in lesion identification or targeting biopsy sites but do not replace COE, histopathology, or clinical judgment.

    • When using devices like VELscope, ViziLite, or GOCCLES, perform and document a full COE and use device findings to inform, not replace, biopsy decisions.
    • Positive adjunctive findings should prompt referral to experienced providers or biopsy when clinically indicated.
    Documentation Required

    Imaging adjuncts do not replace biopsy

    Imaging adjuncts do not replace biopsy — Non-invasive imaging modalities (autofluorescence, fluorescent probes, optical filters) can aid detection and surveillance but cannot replace histopathologic confirmation.

    • Document that imaging was used to assist selection of biopsy site or surveillance; ensure biopsy and histology remain the diagnostic standard.
    • Imaging may improve lesion conspicuity or help target biopsies in OPMD but is not diagnostic alone.
    Documentation Required

    Clinical examination findings and rationale

    Clinical examination findings and rationale — When adjunctive tests are used, document the comprehensive oral examination findings, risk factors, and the clinical rationale for selecting biopsy sites or surveillance rather than immediate biopsy.

    • Document duration of lesion (any abnormality >2 weeks should be reevaluated and considered for biopsy), size, appearance, anatomic location, patient risk factors (tobacco, alcohol, immunosuppression), and device findings.
    • If choosing surveillance instead of biopsy, record the rationale, follow-up interval, and criteria for escalation or biopsy.
    Documentation Required

    Any abnormality in the oral cavity that persists >2 weeks

    Any abnormality in the oral cavity that persists >2 weeks — Lesions lasting longer than 2 weeks should be reevaluated and considered for biopsy; adjunctive test results do not obviate this recommendation.

    • Record follow-up plans and outcomes; persistent lesions, VELscope-positive areas that do not resolve within 2 weeks, or lesions with concerning features warrant further assessment and usually biopsy.
    Documentation Required

    Assay and collection documentation

    Assay and collection documentation — For salivary or other biomarker testing, document the assay platform, specimen collection method, reagent status (e.g., Research Use Only), and analytic validation status in the medical record.

    • Standardize and record saliva collection protocols, storage conditions, and assay kit lot/brand when available.
    • Note if assays use RUO reagents or lack clinical regulatory approval; include these details when submitting claims or prior authorization requests.
    Documentation Required

    Documentation when using adjunctive imaging

    Documentation when using adjunctive imaging — When autofluorescence, chemiluminescence, toluidine blue, or other imaging adjuncts are used, document the COE findings, device observations, targeted biopsy site selection rationale, and subsequent histopathology results.

    • Include device type, settings or protocol used (if available), and whether software quantification was applied.
    • Record referral actions, biopsy dates, and histologic outcomes to support medical necessity and appropriate follow-up.

    Background and Context

    Head and neck cancers account for roughly 5% of tumors, with about half arising in the oral cavity; early detection may reduce morbidity and mortality. Multiple adjunctive detection technologies have been evaluated to improve early identification of oral premalignant and malignant lesions, but current evidence is inconsistent and none of the adjunctive methods listed have sufficient validation to replace standard diagnostic pathways centered on clinical examination and biopsy.

    Definitions and Device Descriptions

    inv-46: ViziLite-Blue — chemiluminescent light oral exam kit cleared by FDA (definition/key features)
    DeviceViziLite-Blue oral examination kit (chemiluminescent light oral exam kit)
    Regulatory statusCleared by the U.S. Food and Drug Administration via 510(k) (FDA clearance as adjunct to visual oral exam)
    ComponentsChemiluminescent light source (ViziLite) plus blue phenothiazine dye to mark lesions
    Intended useAdjunct to conventional head and neck examination for patients at increased risk for oral cancer; aids identification and marking of mucosal abnormalities
    Clinical roleDesigned as an adjunctive identification/marking system to improve lesion visualization, not a replacement for biopsy and histology
    inv-47: VELscope / fluorescence visualization (FV) — hand-held autofluorescence device description
    DeviceVELscope (hand-held autofluorescence device)
    Excitation lightBlue/violet excitation light approximately 400–460 nm (visible light ~430 nm used to excite tissue fluorescence)
    FunctionVisualizes differences in tissue autofluorescence to aid detection of mucosal abnormalities and assist surgical margin delineation
    Regulatory statusReceived 510(k) market clearance; deemed substantially equivalent to ViziLite
    inv-48: Chemiluminescence (ViziLite) — light-based adjunctive screening technique definition and evidence note
    DefinitionLight-based adjunctive screening technique using chemiluminescence to enhance visualization of oral mucosal abnormalities
    Diagnostic accuracy noteMeta-analyses report chemiluminescence sensitivity comparable to or worse than toluidine blue and clinical exam; no added benefit over standard screening in some analyses
    Evidence limitationsExisting reviews include heterogeneous studies (e.g., 16 studies in one meta-analysis) and recommend standardized, controlled studies to determine clinical utility
    inv-49: OraRisk HPV — salivary diagnostic test detecting oral HPV DNA; evidence insufficient for screening
    TestOraRisk HPV (salivary diagnostic test)
    MethodPatient performs saline mouth rinse and expectorates sample sent to laboratory for HPV DNA detection
    Evidence statementCurrent evidence is insufficient to establish clinical value of OraRisk for detecting oral cancer; saliva HPV detection studies show inconsistent results
    inv-50: Adjunctive tests — general definition listing toluidine blue, chemiluminescent devices, autofluorescence, brush cytology, biomarkers
    DefinitionNon-surgical diagnostic aids used alongside visual examination (eg, toluidine blue, chemiluminescent devices, autofluorescence, brush cytology, biomarkers)
    Clinical limitationAdjunctive tests cannot replace scalpel biopsy and histologic assessment; they are aids and not standalone diagnostic replacements
    ExamplesToluidine blue staining, chemiluminescent lighting devices (ViziLite), autofluorescence devices (VELscope), brush cytology, salivary biomarkers
    inv-51: MOP genetic test — commercial genetic test assessing cell abnormalities, HPV, and DNA damage for risk stratification
    TestMOP genetic test (commercially described)
    Components assessedCell abnormalities, HPV status, and DNA damage
    Intended purposeReportedly used to stratify oral cancer risk and recommend increased monitoring frequency
    inv-52: HPV testing in oral cavity — molecular and IHC assays used to detect HPV in oral/oropharyngeal tumors; correlation notes
    AssaysMolecular and immunohistochemical assays used in oral/oropharyngeal tumors (eg, p16 IHC, PCR for HPV16/18 DNA, in-situ hybridization)
    CorrelationCorrelation among different assays may be poor; HPV-driven disease appears uncommon in squamous cell carcinoma of the oral cavity (SCCOC)
    Clinical implicationAssay results and prognostic implications vary by technique; comprehensive interpretation and validation needed
    inv-53: miRNA panels — circulating or tissue microRNA profiles proposed as biomarkers to differentiate OSCC/high-risk lesions
    Biomarker classmiRNA panels (circulating or tissue microRNA profiles)
    Diagnostic performanceMeta-analyses report pooled sensitivities and specificities with AUCs (eg, pooled AUC ~0.832), suggesting potential but requiring larger validation studies
    Current statusPromising diagnostic value for OSCC detection but needs rigorous large-scale validation before routine clinical use
    inv-54: Optical autofluorescence (AF/FV) — noninvasive imaging adjunct to COE with higher sensitivity but limitations
    ModalityOptical autofluorescence / autofluorescence imaging (AF/FV)
    Performance characteristicsHigher sensitivity than clinical exam in many studies but lower specificity; reported sensitivity and specificity vary widely across studies
    Clinical roleNoninvasive adjunct to comprehensive oral exam to increase lesion detection and aid visualization; not sufficiently accurate to replace biopsy
    Devices/examplesVELscope, GOCCLES (autofluorescence filters)
    inv-55: Salivary biomarkers (salivaomics) — panels of DNA, RNA, protein and other molecules in saliva under investigation
    DefinitionSalivary biomarkers (salivaomics): panels of DNA, RNA, protein, cytokines, metabolites and other molecules detectable in saliva
    Discovery statusOver 100 candidate salivary biomarkers have been identified (DNA, RNA, mRNA, proteins, cytokines) but none validated for routine clinical use
    Promise and limitationSaliva is noninvasive and in direct contact with lesions, making it promising for early detection, but standardization, assay validation, and large-scale studies are needed
    inv-56: Salivary biomarkers — molecular signatures in saliva indicating premalignant or malignant processes
    DefinitionMolecular signatures in saliva (DNA, RNA, proteins, cytokines, metabolites) that may indicate premalignant or malignant oral processes
    Clinical statusNumerous candidates identified but further validation required before clinical adoption
    ImplicationMay support noninvasive surveillance or adjunct testing once validated and standardized
    inv-57: Confocal laser endomicroscopy (CLE) — high-resolution imaging technique with reported high pooled sensitivity and specificity
    TechniqueConfocal laser endomicroscopy (CLE)
    Imaging capabilityProvides high-resolution, in vivo imaging of mucosal tissues potentially enabling real-time assessment
    Reported diagnostic accuracySystematic review/meta-analysis reported pooled sensitivity ~95% and specificity ~93% for diagnosing OSCC in included studies
    inv-58: Narrow band imaging (NBI) — endoscopic imaging enhancing mucosal vasculature visualization with promising accuracy
    TechniqueNarrow band imaging (NBI)
    FunctionEndoscopic imaging that enhances visualization of mucosal vasculature to aid detection of dysplasia and malignancy
    EvidenceMeta-analysis reported pooled sensitivity ~91.5% and specificity ~75.7% in selected studies; promising tool though higher-powered prospective studies are needed
    inv-59: 5-ALA induced PPIX — fluorescent probe technique to induce protoporphyrin IX fluorescence for detection of dysplasia/malignancy
    Technique5-ALA induced protoporphyrin IX (PPIX) fluorescence
    MethodAdministration of 5-aminolevulinic acid induces PPIX fluorescence in dysplastic/malignant tissue which can be visualized with fluorescent probes
    PerformanceSystematic reviews report high sensitivity (eg, 90–100%) and variable specificity (eg, 51.3–96%) across studies; may aid detection but does not replace histopathology
    inv-60: Autofluorescence imaging (AFI) — device-based tissue fluorescence visualization (VELscope, GOCCLES) used as adjunct to exam
    DefinitionAutofluorescence imaging (AFI): device-based visualization of tissue fluorescence (eg, VELscope, GOCCLES) used as adjunct to conventional oral exam
    Clinical findingsStudies show increased lesion detection and higher sensitivity than white-light exam in many series, but specificity is variable and unable to replace biopsy
    ExamplesVELscope, GOCCLES optical filter; used to highlight areas of abnormal fluorescence for targeted biopsy or monitoring

    Policy Revision History

    2008-07-01effective_date

    Policy became effective.

    2023-10-11reviewLatest

    Policy was last reviewed.